A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs PK101-001 (Primary) ; PK101-002 (Primary)
- Indications Arthritis
- Focus Pharmacokinetics
- Sponsors PMG Pharm Co Ltd
- 23 May 2019 Status changed from active, no longer recruiting to completed.
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2019 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.